# A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

> **NCT01373164** · PHASE1,PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 170 (actual)

## Conditions studied

- Neoplasms
- Neoplasm Metastasis
- Pancreatic Cancer

## Interventions

- **DRUG:** Galunisertib
- **DRUG:** Gemcitabine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01373164
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2015-11
- **Final completion:** 2016-12
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2018-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01373164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01373164, "A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01373164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*